E10030 aptamer: Clinical Trials

3 terminated, 2 completed. 3 Phase 3, 2 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	3	Terminated 3
Phase 1	2	Completed 2
Phase 2	1	Completed 1

Follow E10030 aptamer: new trials by email Literature Review of E10030 aptamer trials Research Report on E10030 aptamer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab, E10030 - Von Hippel-Lindau Syndrome	Phase 1 / Phase 2	Completed	National Eye Institute (NEI)	3	2017-01-23	2021-11-01
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration	Phase 3	Terminated	Ophthotech Corporation	645	2014-05-01	2024-10-31
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration	Phase 3	Terminated	Ophthotech Corporation	627	2013-08-01	2024-10-30
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration	Phase 3	Terminated	Ophthotech Corporation	619	2013-08-01	2024-10-30
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration E10030 - Age-related Macular Degeneration	Phase 1	Completed	Ophthotech Corporation	18	2007-12-01	2024-02-21

Conditions studied

Macular Degeneration (4)  ·  Choroidal Neovascularization (3)  ·  von Hippel-Lindau Disease (1)

Sponsors

Ophthotech Corporation (4)  ·  National Eye Institute (NEI) (1)

Countries

United States (5)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Brazil (2)  ·  Canada (2)  ·  Colombia (2)  ·  Czechia (2)  ·  Estonia (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Israel (2)  ·  Italy (2)  ·  Latvia (2)

Top investigators

Henry E Wiley, M.D. (1)

Results publications

PMID 30957581, PMID 34549489